- BREAKING NEWS: CMS Announces Coverage Change to Allow Use of CGM Smart Phone Applications
In an important advocacy victory for our members and their patients, we are encouraged to see that Medicare beneficiaries will be able to use smart phone applications in conjunction with their continuous glucose monitors. - Q&A: Daniel Drucker, MD, New Editor-in-Chief, Endocrine Reviews
Beginning July 1, Daniel J. Drucker, MD, will become the new editor-in-chief of Endocrine Reviews. - High Fear of Disease Occurrence, Low Quality of Life Associated Multiple Endocrine Neoplasia Type 1
- Case of the Month: Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline Educational Activity
- Thyroid Dysfunction May Lead to Diabetes during Pregnancy
Early Registration is now open for Endocrine Board Review 2018 taking place September 4–5 in Miami, Florida.
Clinical Endocrinology Update (CEU) will provide you with the opportunity to learn from and network with faculty at the forefront of endocrine practice and research. Early Registration is now open for:
The Endocrine News Podcast, features interviews with experts addressing the latest research and trends in the field of endocrinology.
We unite, lead, and grow the endocrine community to accelerate scientific breakthroughs and improve health worldwide.
Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma
MELK is overexpressed in human adrenocortical carcinoma cells and drives proliferation, tumorigenesis, and survival in a hypoxic environment. MELK is a therapeutic target for patients with ACC.
Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia
Hypoglycemia increases noradrenergic activity in the raphe nuclei, whereas changes in hypothalamic noradrenergic activity correlate with the counterregulatory response to hypoglycemia in humans.
Lessons From the Testosterone Trials
The Testosterone Trials were conducted to determine if testosterone treatment would benefit older men with low testosterone. This report describes the Trials’ development and results and the lessons learned.
Everolimus Directly Suppresses Insulin Secretion Independently of Cell Growth Inhibition
Both a clinical case patient with metastatic insulinoma and in vitro experiments demonstrated that everolimus directly suppresses insulin secretion, independently of its tumor regression effect.